Anti-doping tests conducted at unconventional hours, including during the night, have become a focal point during the Tour de France. These tests are part of an effort to detect micro-dosing, a technique where minuscule amounts of performance-enhancing drugs are used and are cleared from the body within a few hours, leaving a narrow window for detection.
Some experts believe that if cyclists know they are generally not tested during specific nighttime hours, it could present an opportunity for micro-dosing. Jonathan Vaughters, a figure in cycling, explained that a low dose of a peptide hormone could be cleared from the system within four hours, potentially making it undetectable if administered late at night. He also noted that testing technology is advancing, but doping remains a risk as athletes and teams push boundaries.
Vaughters views night testing as a deterrent, stating that while it may be disruptive, limited occurrences once or twice a year can significantly enhance credibility. He added, "One night of lost sleep; lose a little sleep - gain a lot of credibility."
While the era of using EPO and blood transfusions, which often involved nighttime hotel room tests, is thought to be largely behind professional cycling, sophisticated methods like the Athlete Biological Passport (ABP) used by the World Anti-Doping Agency (WADA) are designed to detect inconsistencies. Though there have been recent doping bans, they have not involved high-profile cyclists. Lower tiers of the sport have, however, seen riders caught using EPO and human growth hormones.
The International Testing Agency (ITA), on behalf of the UCI (Union Cycliste Internationale), acknowledged the need to minimize the impact of testing on riders. However, the ITA stated its responsibility to ensure the effectiveness of the anti-doping program and the integrity of cycling races, which may require testing outside standard daytime hours in limited and justified circumstances.